In this randomized controlled trial published in the Journal of Clinical Endocrinology & Metabolism in 2007 (PMID: 17390929), 100 hypogonadal men with type 2 diabetes aged 40–70 were randomized to receive either intramuscular testosterone enanthate (200 mg every two weeks) or placebo for 6 months to evaluate its effects on
